Clinical Trials
407 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
ULTIMO
Cancer Research Antwerp
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
National Institutes of Health Clinical Center (CC)
Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes
University of Colorado, Denver
NAVIGATE
Bayer
ADIE-BC
King's College London
AH-HA
Wake Forest University Health Sciences
MK-4700-001
Merck Sharp & Dohme LLC
CPAQ-8-BC
G. d'Annunzio University
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
EHCancer
Zagazig University
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Effects of a Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active Treatment
University of Salamanca
A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
Case Comprehensive Cancer Center
Efficacy and Safety of Supervised Therapeutic Exercise in Cancer Patients With and Without Concurrent Treatment.
Universidad Complutense de Madrid
IMPLICATION
Centre Hospitalier Universitaire de Besancon
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
ICAN-NC
Duke University
INOVOLINE
Hospices Civils de Lyon
AYAConnect
UNC Lineberger Comprehensive Cancer Center
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Hummingbird Bioscience
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
Institut Curie
AVR-CHEMO
Arab American University (Palestine)
EARN
Washington University School of Medicine
GLIMMER-01
Palleon Pharmaceuticals, Inc.
The Effect of Aerobic Exercise on Selective Biomarkers of Patients With Cancer
Izmir Bakircay University
Symptom Management for YA Cancer Survivors
Duke University
A Guided Written Disclosure Intervention to Promote Post-traumatic Growth in Cancer Patients GUIDED WRITTEN DISCLOSURE
Azienda USL Reggio Emilia - IRCCS
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
SLIM
Batterjee Medical College
Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer
Ottawa Hospital Research Institute
AIM-RÖ
Ostergotland County Council, Sweden
EXODIAG
Centre Georges Francois Leclerc
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
National Institutes of Health Clinical Center (CC)
TARGIT-E
Universitätsmedizin Mannheim
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
IT-01
Intensity Therapeutics, Inc.
MOM
Inova Health Care Services
IIT2020-20-SHIRAZIP-WALK: Nature Walks
Cedars-Sinai Medical Center
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Cedars-Sinai Medical Center
LHRHa
Kastamonu University
SOLAR-1
Novartis
CUPIDON
Institut du Cancer de Montpellier - Val d'Aurelle
CARMA
Cedars-Sinai Medical Center
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Zymeworks BC Inc.
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Compugen Ltd
CheckMate 7FL
Bristol-Myers Squibb
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
ROOT
Taproot Health